ORPHA:1465
Coffin-Siris syndrome
Also known as: CSS
Publications
1,222
Trials
31
Interventional, condition-specific
Researchers
1,464
Distinct authors in sample
Gene link
ARID1A, ARID1B, ARID2
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare genetic syndromic of broad phenotypic range characterized by and variable clinical features which most commonly, but not consistently, include aplasia or hypoplasia of the distal phalanx or nail of the fifth digit, and coarse facial features.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015452
- MeSH:C536436
- UMLS:C0265338
- NCIT:C35321
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — ARID1A, ARID1B, ARID2, BICRA, DPF2…
- LiteraturePresent
1,222 matched papers (981 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
31 matched on ClinicalTrials.gov (13 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (ARID1A, ARID1B, ARID2…).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
1,222
1,222 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
1,222 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
981 in the last 10 years · low confidence
Phrase hits: 1,222 · MeSH hits: 0
Who's working on it?
1,464
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Sadikovic B10 papers · 2026
Verspeeten Clinical Genome Centre, London Health Sciences Centre, London, ON, Canada; Department of Pathology and Laboratory Medicine, Western University, London, ON, Canada.
Papers in Europe PMC - 02Santen GWE8 papers · 2026
Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: santen@lumc.nl.
Papers in Europe PMC - 03Wang Y8 papers · 2026
Center of Molecular Medicine, Pediatrics Research Institute, Children's Hospital of Fudan University, National Children's Medical Center, 399 Wanyuan Road, Shanghai, 201102, China.
Papers in Europe PMC - 04Li Y7 papers · 2026
Department of Neurology and Rehabilitation, Qingdao Women and Children's Hospital, Qingdao University. No. 6 Tongfu Road, Qingdao, Shandong, 266034, China.
Papers in Europe PMC - 05Kerkhof J6 papers · 2026
Verspeeten Clinical Genome Centre, London Health Sciences Centre, London, ON, Canada.
Papers in Europe PMC - 06Li H6 papers · 2026
Ningxia Eye Hospital, People's Hospital of Ningxia Hui Autonomous Region, Third Clinical Medical College of Ningxia Medical University, Yinchuan, China.
Papers in Europe PMC - 07van der Sluijs PJ5 papers · 2026
Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Papers in Europe PMC - 08Zhou Y5 papers · 2026
Neurology Department, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, 201102, China.
Papers in Europe PMC - 09Alders M4 papers · 2025
Department of Human Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Papers in Europe PMC - 10Chen J4 papers · 2026
Department of Respiratory Medicine, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
31
interventional trials for this specific condition
31 interventional trials matched this specific condition name; 13 currently recruiting in our sample.
Data as of 27 July 2026
31 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 95.8th percentile).
low confidence · 95.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
31 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06518564·RECRUITING·Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
Conditions: Endometrial Cancer · ARID1A Gene Mutation · Recurrent Endometrial Carcinoma·Matched via name phrase
- NCT05151588·NOT YET RECRUITING·Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma
Conditions: Sinonasal Carcinoma·Matched via name phrase
- NCT07200947·NOT YET RECRUITING·A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Conditions: SMARCA4-Deficient Tumor · Locally Advanced or Metastatic Non-Small Cell Lung Cancer·Matched via name phrase
- NCT07551635·NOT YET RECRUITING·SMARCA4/2 Inhibitor for POU2F3-Positive SCLC
Conditions: Small Cell Lung Cancer·Matched via name phrase
- NCT06561685·RECRUITING·A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Conditions: Metastatic Solid Tumor · Advanced Solid Tumor · Non-small Cell Lung Cancer · SMARCA4-Deficient Tumor·Matched via name phrase
- NCT07438626·NOT YET RECRUITING·Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma
Conditions: Phase II · Sacituzumab · Tirumotecan · SMARCB1-deficient Renal Medullary Carcinoma·Matched via name phrase
- NCT06617923·RECRUITING·Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Conditions: Ovary Cancer · Fallopian Tube Cancer · Primary Peritoneal Cavity Cancer·Matched via name phrase
- NCT06824363·RECRUITING·ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu
Conditions: Solid Tumor, Adult · Malignant Solid Tumor · Stomach Adenocarcinoma · Esophageal Adenocarcinoma·Matched via name phrase
- NCT07307443·NOT YET RECRUITING·A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.
Conditions: SMARCA4-Deficient Tumor · Locally Advanced or Metastatic Lung Cancer·Matched via name phrase
- NCT06444880·RECRUITING·Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
Conditions: SMARCB1-Deficient Malignancies · Epithelioid Sarcoma · Renal Medullary Carcinoma·Matched via name phrase
- NCT07213557·RECRUITING·Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy
Conditions: Advanced or Metastatic Gastrooesophageal Carcinoma·Matched via name phrase
- NCT05490472·RECRUITING·JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Conditions: Solid Tumors · ER+ Breast Cancer · Triple Negative Breast Cancer, TNBC · ARID1A Gene Mutation·Matched via name phrase
- NCT07284186·RECRUITING·First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Conditions: Esophageal Squamous Cell Carcinoma · Gastric Adenocarcinoma · Gastric Squamous Cell Carcinoma · Gastroesophageal Junction (GEJ) Adenocarcinoma·Matched via name phrase
Observational and natural-history studies
4 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT01238250·RECRUITING·Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight
Conditions: 16P11.2 Deletion Syndrome · 16p11.2 Duplications · 1Q21.1 Deletion · 1Q21.1 Microduplication Syndrome (Disorder)·Matched via name phrase
- NCT07093762·NOT YET RECRUITING·Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC
Conditions: Non Small Cell Lung Cancer·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Coffin-Siris syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Coffin-Siris syndrome" OR "ARID1A" OR "ARID1B" OR "ARID2" OR "BICRA" OR "DPF2" OR "SMARCA4" OR "SMARCB1" OR "SMARCC2" OR "SMARCE1"
Recall-expansion terms: ARID1A, ARID1B, ARID2, BICRA, DPF2, SMARCA4, SMARCB1, SMARCC2, SMARCE1
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 31 interventional · 4 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, recall-expansion; with hits: phrase, recall-expansion
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: CSS
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (1222) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-26T17:28:31.846Z
